Lepu Medical: Rechargeable implantable deep brain stimulation system product has received registration approvalZhitong·Nov 4, 2025 at 08:08 AM300003-2.05%
Lepu Medical: The implanted deep brain stimulation device is expected to be approved for market launch soon and is likely to contribute to revenue next yearZhitong·Oct 27, 2025 at 01:45 AM300003-2.05%
Lepu Medical released its performance for the first three quarters, with a net profit attributable to the parent company of 982 million yuan, an increase of 22.35%Zhitong·Oct 24, 2025 at 02:13 PM300003-2.05%
Lepu Medical: Third-quarter net profit of 291 million yuan, a year-on-year increase of 176.18%Zhitong·Oct 24, 2025 at 11:18 AM300003-2.05%
Lepu Medical signs a strategic cooperation agreement with HanHai InformationZhitong·Sep 22, 2025 at 10:42 AM300003-2.05%
3 Asian Growth Companies With Insider Ownership Expecting Up To 34% Revenue GrowthSimplywall·Sep 19, 2025 at 12:25 AM300003-2.05%09926-1.20%
Lepu Medical: The first subject has been dosed in the Phase II clinical trial of MWN105 injectionZhitong·Sep 4, 2025 at 08:17 AM300003-2.05%
SCIENTECH received a reduction of 11.14 million H shares from its controlling shareholder Lepu MedicalZhitong·Aug 25, 2025 at 11:35 PM02291-2.61%300003-2.05%
Lepu Medical: Subsidiary's injectable cross-linked sodium hyaluronate gel has received NMPA registration approvalZhitong·Aug 25, 2025 at 12:59 PM300003-2.05%
Lepu Medical released its performance for the first half of the year, with a net profit attributable to the parent company of 691 million yuan, a decrease of 0.91%Zhitong·Aug 22, 2025 at 11:10 AM300003-2.05%
Innovative drug concept rebounds after hitting the bottom, Junshi Biosciences and others rise over 5%Zhitong·Aug 8, 2025 at 02:29 AM002020-1.00%300436-1.56%
The blood oxygen monitor sector sees a short-term surge, SDIC hits the limit upZhitong·Aug 7, 2025 at 03:24 AM688130-1.23%300793-1.38%
Lepu Medical: Injection of Recombinant Type A Botulinum Toxin Obtains Drug Clinical Trial Approval NoticeZhitong·Aug 1, 2025 at 11:52 AM300003-2.05%
CITIC Construction Investment: The optimization of centralized procurement policies no longer solely emphasizes low prices; focus on valuation recovery and performance inflection point opportunitiesZhitong·Jul 25, 2025 at 03:22 AM300003-2.05%
